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INTRODUCTION
Th e beginning of 2020 was marked by the emergence 
of the 2019 COVID-19 pandemic (Corona Virus 
Disease from 2019) caused by the new corona virus, 
SARS-CoV-2 (also known as new CoV, 2019-nCoV or 
COVI-19), a name derived from the syndrome name, 
i.e. Severe Acute Respiratory Syndrome, which fi rst 
appeared in China at the end of 2019 (1) and then 
spread rapidly around the world. So far, the animal 
from which the SARS-CoV-2 was transmitted to hu-
mans is not known yet with certainty. In addition to 
the previously known MERS-CoV and SARS-CoV, 
which can cause severe clinical presentation (Middle 
East Respiratory Syndrome and Severe Acute Respi-
ratory Syndrome), four other human coronaviruses 
(229E, NL63, OC43 and HKU1) have been shown to 
cause infection only in the upper respiratory tract and 
cause relatively minor symptoms. SARS-CoV-2 has 
the ability to infect and actively reproduce in the up-
per respiratory tract.
In recent months, physicians and scientists have faced 
new challenges regarding COVID-19 and are focused 
on the investigation of a number of unknown charac-
teristics of the novel coronavirus (its ability to infect 
and reproduce in the respiratory tract) (1), the recep-
tor through which it enters human cells, the immune 
response and accompanying infl ammation, new drugs 
and vaccines (2). As with other pathogens, the outcome 
of infection with SARS-CoV-2 depends on the amount 
of virus exposure at the start of infection, and on the 
innate and adaptive immune capabilities of the host, as 
well as the ability to overcome infl ammation. General-
ly, the immune response is conditioned by age, genetic 
inheritance, and health condition of the host (3). 
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Although COVID-19 initially appeared to be a disease 
of the elderly and individuals whose immune system 
is already compromised by various chronic diseases 
and conditions, it was soon shown that middle-aged 
persons, younger persons and some children can be 
aff ected by this new viral disease. 
Th e aim of this paper is to present literature data on 
the relationship between age and outcome of SARS-
CoV-2 infection. In search of the review and scientifi c 
papers on the PubMed free search engine, the follow-
ing key words were used: age, angiotensin-converting 
enzyme 2 (ACE2), coronaviruses, COVID-19, SARS-
CoV-2. Articles published in English between 2003 and 
May 2020 were included and selected according to the 
relevance to the topic.
SARS-COV-2
Like other coronaviruses, SARS-CoV-2 belongs to the 
betaCoV group of positive-sense single-stranded RNA 
viruses (4, 5), diameter of approximately 60-140 nm, 
having four major structural proteins: the spike (S), 
membrane/matrix (M), small envelope (E) and nucle-
ocapsid (N) proteins, essential to produce a structur-
ally complete viral particle and for infection. Trimeric 
S glycoprotein comprises two subunits, S1 and S2 
subunits. Th e S1 subunit contains an amino-terminal 
domain and a receptor-binding domain (RBD), which 
binds to ACE2 on the surface of epithelial cells in the 
lungs and other tissues. As the S glycoprotein through 
its RBD interacts with human ACE2 as a receptor on 
the target cell and mediates virus-cell fusion, it is re-
sponsible for viral entry into human cells (6). Th e S2 
subunit comprises a fusion peptide region and two 
heptad repeat regions, HR1 and HR2. According to the 
research of other CoVs (7), the M protein defi nes the 
shape of the viral envelope, binds to the S protein and 
the host surface receptors, and therefore it improves 
membrane fusion. In addition, M protein is involved 
in virus replication, and is also important for virus an-
tigenicity (8). Th e N protein has multiple functions: 
it allows virus replication, the host cellular response 
to viral infection, and acts as an antagonist of inter-
feron alpha (IFN-α), a major eff ector cytokine in the 
innate antiviral response (9). Th e majority of E pro-
tein is localized at the site of intracellular traffi  cking. 
It seems that protein E participates in viral assembly, 
intracellular traffi  cking and pathogenesis of the virus 
infection (10). Aft er SARS-CoV infection, B lympho-
cytes produce antibodies against these four structural 
proteins crucial to the development of diagnostic tests 
and vaccine (11). 
ANGIOTENSIN-CONVERTING ENZYME 2 AND 
SARS-COV2 INFECTION
Th e monocarboxypeptidase ACE2 is a multifunction-
al protein that acts in several ways: (i) as an enzyme 
it degrades angiotensin (Ang) 2 to biologically active 
peptide Ang (1-7) in the renin-angiotensin system 
(RAS); (ii) as a receptor for SARS-CoVs, it allows the 
virus to penetrate the cells of various tissues (Figure 1); 
(iii) as an acid transporter plays an essential role in the 
absorption of amino acids in the kidney and gut; and 
(iv) in the soluble form (sACE2) present in serum, it 
degrades angiotensin Ang 2 to Ang (1-7) (12, 13). Al-
though Kuba et al. suppose that the function of ACE2 
as a SARS-CoV receptor takes place independently of 
its peptidase activity (12), this hypothesis needs to be 
proven in the future. ACE2 expression has been found 
in oral and nasal mucosa, lungs, adipose tissue, heart, 
brain, kidneys, vascular tissue, stomach, liver (13-15). 
Also, ACE2 is bound to peptides in circulation (both 
maternal and fetal), renal tubular fl uid, cerebrospinal 
fl uid, interstitial and bronchial fl uid. 
Fig. 1. Protective eff ects of angiotensin-converting enzyme 
2 (ACE2) and detrimental consequences aft er SARS-CoV-2 
infection. (Adapted according to ref. 13)
Since ACE2 was discovered, attention has been fo-
cused mainly on its function and possible roles in hy-
pertension associated kidney and heart diseases and 
in pregnancy, as well as in patients with diabetes (13). 
However, the knowledge of ACE2 to date is still in-
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suffi  cient to comprehend fully all aspects of the action 
of this enzyme, particularly regarding its role in the 
infection with SARS-CoV-2 and all the consequences 
of this infection, including the severity of COVID-19. 
It is located on the outer membrane of epithelial cells 
in the lungs (particularly in type 2 pneumocytes and 
macrophages) (16). Th e entry of SARS-CoV-2 into 
the cell takes place with the simultaneous activity of 
ACE2 and other receptors (co-receptors), such as Mas 
receptors and type II transmembrane serine protease 
receptor (TMPRSS2) (13, 14). SARS-CoV employs the 
TMPRSS2 for S protein priming. It is not yet known 
whether SARS-CoV-2 also employs both ACE2 and 
TMPRSS2 for host cell entry (17). ACE2 associated 
with the Mas receptor plays a benefi cial role because 
it reduces infl ammation and prevents development 
of fi brosis and pulmonary damage (13, 14). However, 
when SARS-CoV-2 enters cells via ACE2 as a receptor 
with consequent endocytosis, this benefi cial eff ect will 
be absent and detrimental consequences will occur in 
the cells into which the virus has entered (Figure 1). 
According to the previous research on SARS-CoV in-
fection, ACE2 has a dual function. It plays a critical 
role in the entry of the virus into cells, and may also 
be involved in post-infectious regulation (18). Th is 
post-infection regulation is supported by data that the 
expression of ACE2 increases 12 hours aft er infection, 
that it continues to increase signifi cantly for 24 hours 
aft er infection, and that aft er 48 hours high expression 
still persists (19). Recently, bioinformatics methodolo-
gy has enabled to identify not only ACE2 expression in 
the lung, but also the potential protein-protein inter-
action network, which regulates the network between 
ACE2 and infl ammatory cytokines (19). 
AGE-DEPENDENT EXPRESSION OF 
ANGIOTENSIN-CONVERTING ENZYME 2
Studies in rat lung tissues have shown that ACE2 ex-
pression in younger animals is signifi cantly higher 
than in adult animals regardless of gender, and that in 
older animals there is a weak decrease in ACE2 ex-
pression in comparison with young and adult animals 
(20). Th ese data would support the notion that ACE2 
has a greater protective role, i.e. anti-atrophy, anti-ox-
idant, anti-infl ammation, etc. in younger individuals, 
as presented in Figure 1. Besides, in the lungs, ACE2 
expression levels and immune signature enrichment 
levels displayed positive correlation in older animals 
and negative correlation in younger animals (20). Re-
search on ACE2 expression in lung tissue is currently 
limited, and is being conducted in animal tissues. To 
defi ne the true role of ACE2 as a receptor for SARS-
CoV-2 in children, adults and elderly patients, further 
research will be needed, presumably on cell cultures 
as well.
INNATE AND ADAPTIVE IMMUNE RESPONSE 
TO SARS-COV-2 VIRUS
SARS-CoV-2 fi rst replicates rapidly in epithelial cells 
of respiratory and enteric system. Once the virus en-
ters the host cells, both non-specifi c (cellular and hu-
moral) and specifi c (cellular and humoral) (21, 22) 
immune mechanisms are activated, as well as the in-
fl ammatory cascade (3, 22). Th e fi rst contact with the 
pathogen leads to the activation of the mechanisms 
of innate immunity, and the achievement of memory 
via memory T helper lymphocytes, in order to initiate 
specifi c immune response in re-contact with the same 
pathogen. Th is response of the adaptive immune sys-
tem is particularly rapid (23).
Experience with SARS-CoV has shown that innate 
immunity is crucial for successful defense against the 
virus (24). It is not yet clear whether the immune/in-
fl ammatory response to SARS-CoV can be projected 
onto SARS-CoV-2, but it can be assumed that there 
is certain parallelism. Th e fi rst reaction of the host af-
ter infection is to limit the spread of the virus in the 
host cells. Dendritic cells, macrophages, IFN-α, innate 
immune mediators, and the complement system are 
involved in this fi rst phase of viral replication control 
(Figure 2). Th e proinfl ammatory reaction takes place 
simultaneously because proinfl ammatory cytokines 
are released from the infected cells, e.g., IL-6, TNF-α 
and IFN-β, which induce direct antiviral response and 
modulate other mediators of innate and adaptive im-
munity (such as NK cells, CD8+ lymphocytes) and the 
complement system (24, 25). Dendritic cells also act 
as antigen presenting cells, followed by the activation 
of naїve T lymphocytes and subsequent activation of 
CD4+ and CD8+ lymphocytes. CD8+ lymphocytes 
stimulate the synthesis of IFN-γ, which inhibits viral 
replication directly. CD4+ lymphocytes are aimed at 
stimulating the infl ammatory response in the lungs 
(hyperinfl ammation). Immunohistochemical analysis 
of patients who died of COVID-19 revealed that de-
ceased patients had atrophy and necrosis of the spleen 
and lymph node cells. In addition, lymphatic tissue 
macrophages contained SARS-CoV-2 nucleoprotein 
antigen and showed upregulation of IL-6, suggesting 
that macrophages may contribute to viral spread, se-
vere infl ammation, and activation-induced lympho-
cytic cell death during COVID-19 (26).
Upon activation, B lymphocytes are involved in the 
immune response by synthesizing specifi c immu-
noglobulins directed against the S and N antigens of 
CoV (27). Patients who manage to synthesize signifi -
cant amounts of antibodies have better outcome of the 
infection (24).
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Fig. 2. Predicted immune response and infl ammation during 
SARS-CoV-2 infection.
Anti-N-IgM/IgG – IgM/IgG antibodies against viral N-antigen; Anti-S-
IgM/IgG – IgM/IgG antibodies against viral S-antigen; ACE2 – angion-
tensin converting enzyme 2; Bly – B lymphocytes; C3a – complement 
component 3a; C5a – complement component 5a; CD4+ – CD4+ T 
helper lymphocytes; CD8+ – CD8+ T helper lymphocytes; IFN – inter-
feron; Mas R – Mas receptor; TMPRSS2 – type II transmembrane ser-
ine protease receptor; TNF α – tumor necrosis factor α; TNF R – tumor 
necrosis factor receptor; Y – antibody; black circle – cytokine
IMMUNITY FROM FETAL LIFE TO OLD AGE
It is generally known that the immune system develops 
over lifetime. At birth, the immune system is relative-
ly immature. In general, neonatal immunity is weaker 
than that of adults because of tissue leukopenia, cell 
intrinsic hyporesponsiveness, and high values of ad-
enosine in extracellular fl uids, and inhibitory mech-
anisms (28). Innate immunity is considered to play a 
more dominant role in protecting against infection in 
childhood than in adulthood. Th e complement system 
represents the backbone of the innate immune system 
(25). In infant serum, the concentration of comple-
ment components does not exceed 80% of the value 
of adults, but some components may reach the value 
in adults already aft er the fi rst month of life (28). In 
the fi rst two decades, the immune system develops to 
a certain degree of maturity, which is maintained in 
adulthood, followed by a gradual decrease or weak-
ening of physiological functions, including those of 
the immune system. Generally, in early adulthood, 
the immune system successfully maintains its balance 
against environmental antigens, suppresses infl amma-
tion, and heals visible and invisible damage to various 
tissues (Figure 3). As age advances, the immune system 
homeostasis becomes weaker, malignant and autoim-
mune diseases can occur due to environmental factors 
in people with genetic predisposition (28). Decline of 
the immune response is a consequence of impaired 
innate and adaptive immunity function and increas-
ing immunosenescence, which is ultimately refl ected 
in reduced phagocytic function, decreased number of 
macrophage precursors, neutrophil dysfunction, and 
impaired function of B and T lymphocytes (23, 28-
30). In addition to immunosenescence, worsening of 
the clinical status of the elderly with COVID-19 is also 
aff ected by systemic chronic infl ammation, known as 
senoinfl ammation (31). Due to senoinfl ammation, the 
values of proinfl ammatory cytokines increase in the 
elderly. In addition, the ability to synthesize specifi c 
antibodies decreases.
Fig. 3. Basic features of the immune response over lifetime. 
Aft er birth, the mechanisms of innate immunity play a major role. As 
the child encounters diff erent antigens, the mechanisms of acquired 
immunity are increasingly emerging. In adulthood, a stable balance 
of the immune system and exposure to numerous antigens is estab-
lished. Th e immune system is increasingly weakening with age, result-
ing in the onset of infl ammation, malignant and autoimmune diseases. 
COVID-19 symptoms worsen with patient age. (Adapted according to 
ref. 22 and 28)
OUTCOMES OF SARS-COV-2 INFECTION 
DEPENDING ON PATIENT AGE
Short-time experience with SARS-CoV-2 infection 
has shown that the initial infectious dose of virus is 
in correlation with more severe disease (32). Children 
and adolescents are the healthiest segment of the en-
tire population and generally have mild symptoms of 
SARS-CoV-2 infection, mainly on upper respirato-
ry airways. If a child with SARS-CoV-2 pneumonia 
does not have another associated disease, COVID-19 
prognosis is good (33). However, in rare cases, chil-
dren may have pneumonia or multisystem infl amma-
tory syndrome (MIS). Th e disease has a more severe 
course in patients with associated chronic diseases 
(cardiovascular diseases, diabetes, chronic respiratory 
diseases, renal disease, coagulopathy, etc.). Th e most 
severe form of the disease, oft en fatal, occurs in the 
elderly, due to more pronounced immunosenescence 
(3). From these observations, it can be concluded that 
people of good general health have milder or mod-
erate symptoms of COVID-19, and that older people 
have more severe symptoms than younger patients, 
which can be interpreted with the functional capacity 
of the immune system (Figure 3). In addition, children 
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have higher expression of ACE2 than adults have and 
are less susceptible to detrimental eff ects of virus than 
older persons are. Moreover, due to low expression of 
ACE2, elderly patients may have more severe COVID- 
19 outcomes, especially those with multiple comor-
bidities (34, 35). Within the kidneys, ACE2 is mostly 
localized in tubular epithelial cells and less in glomer-
ular epithelial cells and in renal vessels (36), where it 
plays a key role in the RAS. Despite the higher levels 
of ACE2 observed in renal epithelial cells than in lung 
epithelial cells, the incidence of acute kidney injury in 
COVID-19 is relatively low (29%), in contrast to 71% 
incidence of severe lung injury. Renal damage could 
result from pre-existing renal diseases in some adult 
patients, and especially older patients (37).
Recent epidemiological studies involving more than 
3,000 children have shown that the majority of patients 
with proven SARS-CoV-2 infection were asymptomat-
ic or had mild and moderate symptoms of COVID-19, 
and a 14-year-old boy died (38-40). Th e initial symp-
toms in children are fever and dry cough, and aft er the 
disease begins to worsen, rhinitis, nasal congestion, fa-
tigue, headache, diarrhea and dyspnea can occur (41). 
Several reasons could aff ect the diagnosis of illness in 
children. Th ese are less exposure of children to the 
source of the infection, milder symptoms of the dis-
ease, sometimes the infection goes through even with-
out signifi cant symptoms, thus laboratory testing for 
the virus is less frequently performed in children (42). 
Mild COVID-19 presentation in children might be 
associated with higher expression of ACE2 and with 
innate immune memory, i.e. trained immunity (im-
munological memory in innate immune pathways) 
(35). It has also been hypothesized that SARS-CoV-2 
infection is less common among children than adults 
because of the lower maturity and function of ACE2 
(38), resulting in a reduced possibility that such less 
functional ACE2 can bind the virus and allow it en-
ter host cell. Diff erences in the immune systems be-
tween children and adults may be another reason why 
children respond to SARS-CoV2 infection diff erently 
from adults. Furthermore, children are more up-to-
date with vaccination, which potentially may protect 
them from other infections due to some non-specifi c 
benefi ts of childhood vaccine (43). 
Changes in the functional capacity of the immune sys-
tem over lifetime are refl ected in the values of partic-
ular immune mediators, such as absolute cell counts 
of B and T lymphocytes, T lymphocyte subsets in pe-
ripheral blood, as well as serum cytokine concentra-
tion (44, 45).
Th e number of NK cells decreases from infancy to 
adulthood, but in the elderly, their number gradually 
increases. In the elderly, the capacity of the antiviral 
cytokine IFN-α decreases. Th e percentage of T lym-
phocytes increases from childhood to adulthood, but 
decreases in the elderly. Regarding proinfl ammatory 
cytokines, the concentration of IL-1, IL-6, IL-8 and 
TNF-α has been shown to increase in old age in com-
parison to adults. At the same time, in the elderly, the 
concentration of Th 1 cytokines (IL-2, IFN-γ) decreas-
es, and the concentration of Th 2 cytokines (IL-4, IL-
10) increases (44, 45).
In the general population, about 80% of infected per-
sons have mild signs and symptoms (tiredness, fe-
ver, cough, loss of taste and smell, headache). Other 
patients, i.e. those already suff ering from a serious 
chronic illness (hypertension, diabetes, cardiovascular 
disease, chronic respiratory disease, and chronic renal 
disease) and the elderly are at a high risk of developing 
a severe form of the disease (acute respiratory distress 
syndrome (ARDS), nausea, vomiting, diarrhea) with 
possible lethal outcome (1, 46, 47). In individuals with 
impaired immunity, SARS-CoV-2 will almost undis-
turbed cause massive destruction of target tissues, es-
pecially in the organs with ACE2 expression, such as 
the lungs, intestines, and kidney. Due to infl ammation 
damaging, pneumonia is the main cause of life-threat-
ening respiratory disorders in the severe stage of the 
disease. 
Elderly patients with associated diseases, such as hy-
pertension, cardiovascular (arrhythmia) and cerebro-
vascular disease, chronic obstructive pulmonary dis-
ease (COPD), are at a high risk of death, with dyspnea 
being a key symptom (48). Th e main predictors of 
death are complications that occur in these patients, 
such as acute cardiac injury and cardiac insuffi  ciency, 
arrhythmia, acute renal injury, ARDS, and bacterial 
infection.
LABORATORY FINDINGS
Th e aim of laboratory diagnosis in patients with 
SARS-CoV2 infection is to prove the presence of the 
virus in biological samples (nasopharyngeal and oro-
pharyngeal swab or wash in outpatients and sputum 
and/or endotracheal aspirate or bronchoalveolar la-
vage (BAL) in inpatients), to assess the patient’s gen-
eral health status of target organs, immune status, and 
intensity of infl ammation.
A. DETECTION OF SARS-COV-2
Th e gold standard for the detection of SARS-CoV-2 
is the nucleic acid amplifi cation testing (NAAT) by 
real-time polymerase chain reaction (rtPCR) and fur-
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ther confi rmed by next-generation sequencing (49). 
A positive result establishes whether the individual is 
currently infected with SARS-CoV-2. 
B. MONITORING PATIENT HEALTH STATUS 
Complete blood count (CBC), basic metabolic panel, 
panels for assessment of cardiac and renal function, 
coagulation tests, and indicators of infl ammation are 
determined to assess the general health of the patient 
and screening for underlying diseases. Since children 
generally do not have associated diseases, changes in 
laboratory parameters are typical for viral infection. 
Children with MIS may have lymphopenia, neutro-
philia, increased lactate dehydrogenase (LDH), C-re-
active protein (CRP), ferritin, fi brinogen, procalci-
tonin, D-dimer, IL-6 and decreased albumin values 
(50, 51). It could be assumed that otherwise healthy 
adults will have the same changes in laboratory fi nd-
ings, except for those fi ndings that relate to changes 
caused by simultaneous damage to particular organs, 
e.g., cardiac and renal damage (Table 1) (41, 52 ).
Non-specifi c hematologic and biochemical fi ndings 
depend on comorbidities and therefore on the severity 
of the disease (53). Accordingly, risk factors for sever-
ity of COVID-19 in adults/elderly are lymphopenia, 
neutrophilia, increased LDH, CRP and proinfl amma-
tory cytokines (54). It has also been established that 
older men who have heart damage and those with 
higher LDH may have an increased risk of death from 
COVID-19. In severe infl ammatory state, inpatients 
may have a number of coagulation abnormalities (i.e. 
hypercoagulability) such as thrombocytosis, increased 
prothrombin time, fi brinogen, D-dimer, factor VIII 
(55).
Signifi cant diff erences were found in laboratory fi nd-
ings between the dead and survivors. Longitudinal 
monitoring has shown that patients with worsening 
CBC (lymphopenia, thrombocytopenia, monocytope-
nia, neutrophilia), coagulation (partial thromboplas-
tin time, D-dimer), increased biochemical parameters 
(aspartate aminotransferase, urea), myocardial injury 
markers (creatine kinase-MB, high sensitive tropo-
nin), infl ammatory markers (CRP, IL-6), cellular im-
munity marker (CD4+), and bacterial infection mark-
er (procalcitonin) have an increased risk of death (48). 
Table 1. 
Changes in common laboratory tests and their clinical 
signifi cance
LABORATORY FINDING POTENTIAL CLINICAL SIGNIFICANCE
Detection of SARS-CoV-2
Molecular diagnostics
SARS-CoV-2 (positive) Confi rmed SARS-CoV-2 infection
Health assessment
Hematology
Leukocytes,  or  , S
Lymphocytes, , S, D
Neutrophils,  , S, D
Monocytes, , S, D
MDW, 
Platelets, , S, D
Hemoglobin, 
Reduced immune response to the virus 
Reduced immune response to the virus
Secondary bacterial infection
Severe viral infection/viral sepsis
Consumption (disseminated)/coagulopathy
Possible anemia during acute infection
Coagulation
Prothrombin time, , S, D
D-dimer, , S
Activation of coagulation and/or disseminated 
coagulopathy
Activation of coagulation and/or disseminated 
coagulopathy
Biochemistry
LDH, , S, D
AST, , A ALT , S, D 
Bilirubin, ; 
Fibrinogen, , A, S
Albumin, , S
Urates, , S
Creatinine, urea, , A, S, D
CK-MB, hs-troponin, , A, S, D
pro-BNP, BNP, , A
Pulmonary injury and/or multisystem damage




Impaired liver function, secondary bacterial 
infection, septic shock
Renal injury, oxidative stress
Renal injury




Acute phase proteins, 
C-reactive protein, , S, D
IL-6, IL-10, , S, D
Tumor necrosis factor- , 
Procalcitonin, , S, D
Ferritin, , S
Infl ammation, reactive thrombocytosis
Infl ammation
Acute infl ammation (<6 days)
Viral infection; secondary bacterial infection 
Proportional to the severity of infl ammation
Proportional to the severity of infl ammation
Secondary bacterial infection and progression 
of the severity
Viral infection; secondary bacterial infection; 
Immunity status
Natural killer cells, 
T lymphocyte subsets, , S, D
B lymphocytes, 
Specifi c IgM antibodies, 
Specifi c IgG antibodies, 
Innate immunity; possible impaired cellular 
immunity 
Adaptive immunity; possible impaired cellular 
immunity
Adaptive immunity; possible impaired humoral 
immunity
Indicator of (acute) contact with SARS-CoV-2
Indicator of former contact with SARS-CoV-2
A – typical fi nding in adult/old patients; BNP – B-type natriuretic pep-
tide; AST – aspartate aminotransferase; ALT – alanine aminotransfer-
ase; CK-MB – creatine kinase-myocardial band; hs – high sensitive; D 
– death risk; LDH – lactate dehydrogenase; MDW – monocyte volume 
distribution width; S – proportional to the severity of infl ammation; 
SARS-CoV-2 – Severe Acute Respiratory Syndrome-CoronaVirus-2. 
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C. DETECTION OF ANTIBODIES AGAINST 
SARS-COV-2 ANTIGENS 
About 10 days aft er the onset of symptoms, specifi c 
IgM and IgG antibodies to N, E, M and S antigens of 
SARS-CoV-2 can be detected in patient serum (56). 
Th e maximum value of antibodies is reached in the 
middle of the third week from the onset of the dis-
ease. Aft er this time, the antibody values gradually de-
crease. IgM antibodies reach the lowest values about 
fi ve weeks aft er the onset of the disease and disappear 
from the circulation in the seventh week aft er the on-
set of the disease. Th e decrease in IgG antibodies is 
slower and begins about seven weeks aft er the onset 
of symptoms (57). Compared to the PCR method, de-
termination of antibodies to N antigen has the highest 
diagnostic sensitivity and to S antigen the greatest di-
agnostic specifi city (56, 58).
FINAL REMARKS 
At the time of writing this article, the scientifi c com-
munity has not reliably investigated all the charac-
teristics of SARS-CoV-2 and the host immune and 
infl ammatory response. Currently, there is very lim-
ited knowledge about the host immune response to 
SARS-CoV-2 infection. For now, conclusions on how 
the body copes with the virus are largely based on the 
knowledge about previous coronaviruses.
Th e virus has been shown to have the ability to infect 
the host, enter cells via ACE2, and actively reproduce 
in the respiratory tract and primarily cause pneu-
monia. Children constitute a small fraction of indi-
viduals with COVID‐19, and have a milder form of 
the disease, probably due to higher ACE2 expression 
than adults, successful action of mediators of innate 
immunity (i.e. trained immunity) and higher number 
of decisive lymphocytes in the fi rst years of life. Fur-
ther research is needed to examine the true function 
of ACE2 in SARS-CoV-2 infection. 
Most healthy adults have mild symptoms. In patients 
with comorbidities (hypertension, cardiovascular and 
cerebrovascular disease, COPD), the virus will cause 
more severe forms of the disease. Lymphopenia in 
patients with severe disease occurs mainly due to a 
decrease in the number of T lymphocytes. Elderly pa-
tients are at a risk of death, with worsening laboratory 
fi ndings that indicate cardiac and renal damage, severe 
infl ammation, and decreased immune function. 
Explaining the mechanisms of immunosenescence 
and infl amm-aging may help better understand not 
only age-related disorders and diseases but also SARS-
CoV-2 infection. Attention has been paid to determin-
ing diagnostic sensitivity, specifi city and predictive 
value of certain biomarkers of infl ammation, as well as 
the possible biomarkers of senescence and aging. 
Determination of anti-SARS-CoV-2 antibodies (IgM 
and IgG classes) has no diagnostic value, but serves to 
assess the host’s humoral response, to retrospectively 
assess the individual’s exposure to the virus, and for 
epidemiological purposes. In order for the serologic 
test to precisely distinguish SARS-CoV-2 infection 
from infection with other coronaviruses, future re-
search should examine cross-reactivity in antibody 
binding to specifi c antigens of diff erent viruses. 
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RSARS-CoV-2 (engl. Severe Acute Respiratory Syndrome Coronavirus 2), novi virus iz skupine RNA betakoronavirusa, 
odgovoran je za zoonotsku bolest nazvanu COVID-19 (bolest uzrokovana koronavirusom iz 2019.). Glavni receptor pomoću 
kojega virus ulazi u stanicu domaćina je angiotenzin konvertirajući enzim 2 (ACE2), poznat kao multifunkcionalni protein. 
Receptor ACE2 prisutan je u oralnoj i nosnoj sluznici, plućima, masnom tkivu, srcu, mozgu, bubrezima, vaskularnom tkivu, 
želucu, jetri. Nakon ulaska virusa u ciljne stanice domaćina pokreću se dva procesa, imunosni odgovor domaćina i upalna 
kaskada. Budući da se imunosni (urođeni i stečeni) i upalni odgovori tijekom života mijenjaju u kvalitativnom i kvantita-
tivnom smislu, oba procesa su odgovorna za različit stupanj ozbiljnosti bolesti, ovisno o pacijentovoj dobi. Kratkotrajno 
iskustvo s infekcijom uzrokovanom virusom SARS-CoV-2 pokazalo je da: (i) djeca i adolescenti razvijaju bolest s blagim 
simptomima, uglavnom na gornjim dišnim putevima; (ii) bolest ima teži tijek u odraslih bolesnika s pridruženim kroničnim 
bolestima kao što su kardiovaskularne i bubrežne bolesti, kronične respiratorne bolesti, dijabetes i sl.; (iii) najteži, često 
fatalni oblik pojavljuje se u starijih osoba zbog izraženijih procesa imunosenescencije i upale pri starenju.
Ključne riječi: starija dob, angiotenzin konvertirajući enzim2 (ACE2), koronavirusi, COVID-19, SARS-CoV-2
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